Skip to main content
. 2020 Mar 7;20:61. doi: 10.1186/s12871-020-00978-z

Table 4.

Adverse events

Adverse events N (%) 95% CI
PONV 20 (0.58) 0.30–0.80
Significant SpO2 reduction 6 (0.17) 0–0.30
Upper airway obstruction 3 (0.09) 0–0.20
Rash 2 (0.06) 0–0.10
Bradycardia requiring drug intervention 1 (0.03) 0–0.10
Delayed awakening 1 (0.03) 0–0.10